Introduction
Primary liver cancer was the leading cancer in Thailand in men and the third in women in the period 1998-2000 (Khuhaprema et al., 2007) . Primary liver cancer comprises two major types of cancer-hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) (Sripa and Pairojkul, 2008) . CCA is the second most common type of primary liver cancer, the latter accounting for 5% of all primary cancer in most areas of the world (Craig et al.,1989) . However, in Thailand, especially in Khon Kaen province situated in the Northeastern region there is a very high prevalence of CCA with age-standardized annual incidence rates of 36.3 and 87.7 per 100,000 population in females and males, respectively (Khuhaprema et al., 2010) and is the most common cause of death from cancer (Vatanasapt et al., 1990) .
Most CCA patients see a physician in the late stage of disease, because the tumours are clinically silent in early stages, and clinically this results in poor prognosis (Mihalache et al., 2010) A previous study of survival in CCA patients focused on specific groups, such as those receiving surgical excision and had diagnosis in early state (Pattanathien et al., 2013; Sriputtha et al., 2013) but studies of results of supportive treatment have been limited. Most CCA patients see the physician only one time and are lost to follow up. The aim of this study was to evaluate the survival of CCA patients diagnosed in a late stage and receiving supportive treatment in Northeastern Thailand. improvement of methods for early diagnosis of CCA.
Materials and Methods
A retrospective cohort study was conducted with 746 patients who were diagnosed (at least ultrasonography) and treated by supportive treatment during the period 1 January 2009 to 31 December, 2009 at Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Northeastern Thailand. The patients were followed up until death or the end of the study (30 June, 2011) . The independent variables were age at diagnosis, gender, stage of disease, distant metastasis, histological grading and treatment. The dependent variable was the survival time of patients with cholangiocarcinoma. In order to calculate date of diagnosis and the follow-up period ended when patients died. Censor, patients who were still alive at the end of the study or lost to follow-up, status of each patient was checked from medical records and by linkage with the death registry of the national statistics database.
Descriptive statistics was used for exploratory data analysis. Percentages were used to describe categorical data and means with standard deviations or medians with ranges were used to describe continuous data. The observed survival rate was calculated by the Kaplan-meier method.
(CIs) and the log-rank test were used for comparisons between groups. The Cox proportional hazard regression model was used to assess associations between the various independent variables (covariates) and survival, and the set as p<0.05. All analyses were performed using STATA version 10.0 (StataCorp LP, 2007) The research was approved by the Khon Kaen University Ethics Committee for Human Research (reference no. HE551380)
Results
Regarding the characteristics of the 746 CCA patients included in the study, most were male (68.4%), and the mean age was 60.7 years. Summarized are details for features such as stage of disease, distant metastasis, histological grading and treatment. Most patients were at a late stage (stage IV 52.2%, unknown 44.1%), with distant metastasis M1 in 50.8% (unknown 42.5%) those receiving only supportive treatment were 67.0%, with partial surgery/percutaneous drainage in 16.6% and chemotherapy in 6.4%. By the end of the study, 637 (85.4%) had died. With a total follow-up time of 5,878 person-months, the mortality rate was therefore 10.8 per 100 person-years. Tables 1 and 2 and Figure 1 present the survival rates, survival times and factors affecting survival after supportive treatment. The cumulative 3, 6, 9, 12 and 24 months survival rates were 59.1% (95% CI: 55.5-62.6), 38.6% (95% CI: 35.1-42.1), 30.7% (95% CI: 27.4-34.1), 23.9% (95% CI: 20.9-26.9) and 14.4% (95% CI: 11.9-17.1), respectively. The median survival time after supportive treatment was 4 months. After adjustment for the variables gender, age, stage of disease, distant metastasis, histological grading and treatment of the 
Discussion
The present analysis of the various factors that affected the survival of CCA patients after adjusted variables: gender, age, stage of disease, distant metastasis, histological grading and treatment, found that stage of disease was the factors that affect the survival of CCA patients who had supportive treatment. CCA patients in stage III and stage IV were 6.78 fold at risk of death of CCA patients in stage I and stage II, which is consistent with the study of Vern-Gross et al. (2010) who found that CCA patients with no distant metastasis, survival rates were higher than CCA patients with metastases, and Madariaga et al. (1998) found that in CCA patients with multiple tumour nodules, the risk of death was 3.5 fold than CCA patients with a single tumour mass. This means that the stage of disease of CCA patients were in late stage had a higher risk of death than in early stage. However, although CCA patients in the late stage of the disease, supportive treatment can help CCA patients relieve symptoms and improve the patient's quality of life, lead to end-stage patients with minimal suffering.
In term of survivals of CCA patients who had supportive treatment, the survival rate at 3, 6, 9, 12 and 24 months were 59.1 %, 38.6, 30.7, 23.9 and 4.14, respectively , and the median duration of survival posture to 4 months (95% CI: 3.6-6.4), which differs from the study of Park et al. (2011) who found that the median duration of survival is 21 months and survival rate in the spread of cancer to other organs, the prognosis is not good. Kawarada et al. (2002) found that the survival rate of surgery and did not had spread of cancer to lymph nodes, CCA patients in the early stages of the disease, the survival rate is greater than in this present study. Knupel et al. (2011) found that giving chemotherapy, median survival time was 9.2 months, which is not much different from this study, found that the chemotherapy, median survival was 5.9 months and found that chemotherapy combined with other treatment methods, increased the survival of CCA patients. The median survival time of CCA patients after supportive treatment found in this study is 4 months which is lower than those CCA patients after surgical treatment; 15 and 12.4 months respectively (Pattanathien et al., 2013; Sriputtha et al., 2013) .
However, the results of this study may be different with other studies; variables affecting treatment and survival outcomes, such as the numbers of samples, the duration of the study and data collection, medical knowledge, medical treatment and technology, some studies used a period of follow up to 20 years, but some studies use a one year follow-up and treatment has varied by country, physician and patient post diagnosis status.
In conclusion, stage of disease was an important prognosis factor affecting survival of CCA patients who had diagnosis in late stage. The encourage patients to see health personnel at early stage is very important.
